David B. Frennesson

<i>In vitro</i> and <i>In vivo</i> Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417

Paul Haluska, Joan M. Carboni, David A. Loegering et al. · Cancer Research · 2006 · 177 citations

Medicine, Oncology, Pharmacology +15

Discovery of a 1<i>H</i>-Benzoimidazol-2-yl)-1<i>H</i>-pyridin-2-one (BMS-536924) Inhibitor of Insulin-like Growth Factor I Receptor Kinase with in Vivo Antitumor Activity

Mark D. Wittman, Joan M. Carboni, Ricardo M. Attar et al. · Journal of Medicinal Chemistry · 2005 · 135 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Discovery of a 2,4-Disubstituted Pyrrolo[1,2-<i>f</i>][1,2,4]triazine Inhibitor (BMS-754807) of Insulin-like Growth Factor Receptor (IGF-1R) Kinase in Clinical Development

Mark D. Wittman, Joan M. Carboni, Yang Zheng et al. · Journal of Medicinal Chemistry · 2009 · 94 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Synthesis of a rebeccamycin-related indolo[2,3-a]carbazole by palladium(O) catalyzed polyannulation

Mark G. Saulnier, David B. Frennesson, Milind Deshpande et al. · Tetrahedron Letters · 1995 · 92 citations

Natural Sciences, Chemistry, Medicinal Chemistry +10

Discovery of a Fluoroindolo[2,3-<i>a</i>]carbazole Clinical Candidate with Broad Spectrum Antitumor Activity in Preclinical Tumor Models Superior to the Marketed Oncology Drug, CPT-11

Mark G. Saulnier, Balu Balasubramanian, Byron H. Long et al. · Journal of Medicinal Chemistry · 2005 · 36 citations · Full text

Medicine, Oncology, Pharmacology +8